Bulk Pharmaceutical API Sources for tirofiban hydrochloride

Bulk Pharmaceutical API Sources for tirofiban hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-823-927
Amadis Chemical		A807902
AbaChemScene		CS-0948

Tirofiban Hydrochloride API Sourcing Landscape

Last updated: February 19, 2026

Tirofiban hydrochloride, a platelet aggregation inhibitor, is primarily manufactured by a limited number of specialized API producers. Key players include companies in China and India, with some European and North American presence. Market concentration indicates that sourcing strategies require careful vetting of quality, regulatory compliance, and supply chain reliability.

What are the primary sources for Tirofiban Hydrochloride API?

The global supply of tirofiban hydrochloride API is concentrated among a few manufacturers. The majority of production is located in Asia, specifically China and India, which benefit from lower manufacturing costs and established chemical synthesis infrastructure.

• China: Several Chinese manufacturers are significant suppliers. These companies often possess large-scale production capabilities and have developed expertise in complex organic synthesis. Examples of companies that have historically been involved in API production relevant to cardiovascular drugs include those located in major chemical industrial parks.
• India: Indian pharmaceutical companies, particularly those specializing in generics and APIs, are also key sources. India's strong regulatory framework and growing R&D capabilities support consistent API production meeting international standards.
• Europe and North America: While less dominant in volume compared to Asia, some European and North American companies may also produce or supply tirofiban hydrochloride API, often focusing on niche markets or higher-value, custom synthesis. These sources may offer distinct advantages in terms of proximity to certain end markets or adherence to stringent local regulatory requirements.

What are the typical manufacturing capacities and scales?

Manufacturing capacities for tirofiban hydrochloride API vary by producer, reflecting their investment in infrastructure and market demand. Production typically occurs in multi-purpose chemical synthesis plants capable of handling the required reaction steps.

• Batch Sizes: Typical batch sizes can range from tens of kilograms to several hundred kilograms, depending on the specific synthetic route and the scale of the manufacturing facility. This flexibility allows producers to cater to both smaller clinical trial needs and larger commercial volumes.
• Annual Output: While specific figures are proprietary, leading API manufacturers can achieve annual outputs in the multi-ton range to meet global demand for the drug. This scale is supported by dedicated production lines or flexible multi-purpose equipment.
• Technology: The synthesis of tirofiban hydrochloride involves multiple chemical steps, including amidation, cyclization, and salt formation. Manufacturers invest in advanced synthesis technologies, such as flow chemistry or optimized batch processes, to enhance yield, purity, and cost-effectiveness. Quality control systems, including high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR), are integral to the manufacturing process.

What are the regulatory and quality considerations for API sourcing?

Sourcing tirofiban hydrochloride API necessitates strict adherence to regulatory standards and robust quality management systems. Regulatory bodies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose rigorous requirements on API manufacturing.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with current Good Manufacturing Practices (cGMP). This includes requirements for facilities, equipment, personnel, documentation, and quality control. Audits by regulatory agencies and end-product manufacturers are common to verify GMP compliance.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, quality control, and stability of the API. End-product manufacturers reference these DMFs in their drug applications.
• Certificates of Analysis (CoA): Each batch of tirofiban hydrochloride API must be accompanied by a CoA, detailing critical quality attributes such as purity, assay, impurity profiles, residual solvents, and physical characteristics.
• Impurity Profiling: Rigorous control and characterization of impurities are essential. Regulatory guidelines set limits for known, unknown, and genotoxic impurities. Manufacturers must demonstrate a thorough understanding and control of their synthetic process to minimize impurity formation.
• Stability Studies: Comprehensive stability data is required to establish the retest period or expiry date of the API under defined storage conditions.

Which specific companies are prominent API suppliers?

Identifying specific, consistently active suppliers of tirofiban hydrochloride API requires ongoing market intelligence due to the dynamic nature of the API manufacturing landscape. However, based on general industry trends and typical producers of similar cardiovascular APIs, the following categories of companies are likely engaged in its supply:

• Major Chinese API Manufacturers: Companies with extensive portfolios in cardiovascular drugs and a strong export presence. These entities often operate large-scale facilities and have established relationships with global pharmaceutical firms.
• Leading Indian Generic API Producers: Several Indian companies are recognized for their expertise in producing high-quality generic APIs. Their focus on cost-effectiveness and regulatory compliance makes them significant players.
• Specialized Chemical Synthesis Companies: Smaller to medium-sized companies, potentially in Europe or North America, that offer custom synthesis services for complex APIs like tirofiban hydrochloride, particularly for niche applications or early-stage development.

Specific company names and their current production status can be obtained through specialized market research databases and direct engagement with API manufacturers. Due diligence, including site audits and thorough review of regulatory documentation, is critical when selecting a supplier.

What are the common synthetic routes and potential challenges?

The synthesis of tirofiban hydrochloride is a multi-step process requiring precise control over chemical reactions. Common synthetic strategies aim for efficiency, high purity, and cost-effectiveness.

• Key Synthetic Steps:

  1. Formation of the Tyrosine Derivative: Synthesis often begins with a protected tyrosine derivative.
  2. Amidation: Reaction with 4-(4-piperidinyl)butyric acid ester or a similar precursor to form the central amide bond.
  3. Cyclization: Introduction of the piperidine ring and formation of the cyclic guanidine structure. This step is critical for establishing the core tirofiban molecule.
  4. Deprotection: Removal of protecting groups from the amine and carboxylic acid functionalities.
  5. Salt Formation: Conversion to the hydrochloride salt to enhance solubility and stability.

• Potential Synthesis Challenges:

  • Stereochemistry: Maintaining the desired stereochemistry if chiral intermediates are used. Tirofiban hydrochloride itself is not chiral, but some synthetic routes might involve chiral precursors.
  • Impurity Control: Formation of related substances, such as positional isomers or incompletely reacted intermediates, needs careful monitoring and control through optimized reaction conditions and purification techniques.
  • Yield Optimization: Achieving high overall yields across multiple synthetic steps is crucial for economic viability.
  • Scale-Up: Transferring a synthetic process from laboratory to commercial scale can present challenges in heat transfer, mixing, and reaction kinetics, requiring significant process engineering expertise.
  • Raw Material Sourcing: Reliable sourcing of key starting materials and reagents with consistent quality is essential to avoid process variability.

What are the price ranges and market dynamics?

The pricing of tirofiban hydrochloride API is influenced by several factors, including production costs, regulatory compliance, market demand, and competitive landscape.

• Price Range: While exact pricing is proprietary and subject to negotiation, API prices for complex molecules like tirofiban hydrochloride can range from several hundred to a few thousand U.S. dollars per kilogram. This variability depends on the quantity purchased, the supplier's cost structure, and the level of regulatory documentation provided.
• Market Demand: Demand is driven by the use of tirofiban hydrochloride in acute coronary syndromes. The prevalence of cardiovascular diseases and the availability of alternative treatments influence market size.
• Competitive Landscape: The presence of multiple manufacturers, particularly from cost-competitive regions like China and India, exerts downward pressure on prices. However, suppliers with strong regulatory track records and reliable supply chains can command premium pricing.
• Intellectual Property: While the primary patents for tirofiban may have expired, any novel polymorphic forms, improved synthesis processes, or new formulations could still be under patent protection, influencing market entry and pricing for specific suppliers.
• Supply Chain Disruptions: Geopolitical events, trade policies, or unforeseen production issues can impact supply and lead to price volatility. Diversifying suppliers can mitigate these risks.

Key Takeaways

• Tirofiban hydrochloride API production is concentrated among a few global manufacturers, predominantly in China and India.
• Sourcing necessitates rigorous adherence to cGMP standards, review of DMFs, and validation of supplier quality systems.
• Key synthetic challenges include impurity control, yield optimization, and successful scale-up.
• Pricing is influenced by production costs, regulatory compliance, and market competition, with potential ranges from hundreds to thousands of dollars per kilogram.

FAQs

1. How can I verify a potential supplier's cGMP compliance for tirofiban hydrochloride API? Verification involves reviewing their regulatory inspection history (e.g., FDA Form 483, EMA inspection reports), conducting on-site audits of their manufacturing facilities, and assessing their quality management system documentation.

2. What is the typical lead time for ordering commercial quantities of tirofiban hydrochloride API? Lead times can vary significantly based on the supplier's existing production schedule, inventory levels, and the specific quantity ordered, but typically range from 8 to 20 weeks.

3. Are there any specific polymorphic forms of tirofiban hydrochloride that are preferred or patented? While specific patent details for polymorphic forms require detailed patent landscape analysis, manufacturers aim for stable and consistent polymorphic forms that meet dissolution and stability requirements. Any novel or patented forms would necessitate specific licensing or sourcing agreements.

4. What are the critical quality attributes for tirofiban hydrochloride API that should be included in the Certificate of Analysis (CoA)? Critical quality attributes typically include assay, purity (e.g., by HPLC), specific impurity limits (related substances, residual solvents), water content, particle size distribution (if relevant for formulation), and microbial limits.

5. How do fluctuating raw material costs impact the price of tirofiban hydrochloride API? Significant price fluctuations in key starting materials or reagents can directly influence the cost of goods sold for API manufacturers, potentially leading to upward pressure on tirofiban hydrochloride API pricing if those costs are not effectively managed through long-term contracts or process efficiencies.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry on Drug Master Files. Retrieved from [FDA Website] [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1995). Impurities: Guidelines for Residual Solvents Q3C(R4). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). Impurities: Guideline for Residual Solvents Q3C(R6). [5] Pharmaceutical Technology Industry Reports. (Various Years). Market analysis and supplier directories for active pharmaceutical ingredients.